Skip to main content
Oxford University Hospitals NHS Foundation Trust

This site is best viewed with a modern browser. You appear to be using an old version of Internet Explorer.

Natural adaptive immunity to high risk human papillomavirus (HR HPV) study

Trial categories: Immunity; Infection; Vaccines

Sponsoring organisation: University of Oxford

Defining the high risk human papillomavirus (HR HPV) specific T-cell repertoire in human subjects using a proteome wide approach

Are you interested in taking part in a clinical study that aims to find out how the immune system clears HR HPV, the viruses that cause cervical cancer?

We are looking for women aged 16-24 years who are in good health.

If you agree to take part, we will ask you to attend a maximum of 4 study visits over 1 year. We will ask you to provide a blood sample and a vaginal self-sample at each visit.

You will be compensated for your time and for the additional travelling costs to and from the hospital.

A response to this advertisement will be recorded but carries no obligation to take part.

Please contact the research team for more information:


Back to list of trials